CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Adenosine signalling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response

(2020) Ben Sidders et al.   CLINICAL CANCER RESEARCH

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

(2020) Sohyun Hwang et al.   Scientific Reports

The adenosine pathway in immuno-oncology

(2020) Bertrand Allard et al.   Nature Reviews Clinical Oncology

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

(2019) Siqi Chen et al.   Nature Communications

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer

(2019) Y Kudo et al.   ANNALS OF ONCOLOGY

Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin–Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform

(2019) Zhenhao Qi et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73)

(2019) Marquet Minor et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

(2019) Luca Mazzarella et al.   EUROPEAN JOURNAL OF CANCER

CD73: an emerging checkpoint for cancer immunotherapy

(2019) Siqi Chen et al.   Immunotherapy

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

(2019) Sylvie Lantuejoul et al.   Journal of Thoracic Oncology

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

(2018) Feifei Teng et al.   CANCER LETTERS

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

(2018) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma Tumors

(2018) Edwin Roger Parra et al.   Journal of Thoracic Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

(2018) Limo Chen et al.   Cancer Discovery

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

(2018) Patrick Danaher et al.   Journal for ImmunoTherapy of Cancer

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Immuno-Oncology: Emerging Targets and Combination Therapies

(2018) Henry T. Marshall et al.   Frontiers in Oncology

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

The immune contexture in cancer prognosis and treatment

(2017) Wolf H. Fridman et al.   Nature Reviews Clinical Oncology

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

(2017) Yusuke Inoue et al.   Oncotarget

Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives

(2017) Paola de Andrade Mello et al.   Frontiers in Immunology

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

(2016) H. Kadara et al.   ANNALS OF ONCOLOGY

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients

(2016) E. R. Parra et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

The Roles of CD73 in Cancer

(2014) Zhao-wei Gao et al.   Biomed Research International

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

(2013) Alberto L Horenstein et al.   OncoImmunology

CD73 and adenosine generation in the creation of regulatory microenvironments

(2012) F. S. Regateiro et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome

(2011) Luisa M. Solis et al.   CANCER

Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features

(2010) L. M. Solis et al.   CLINICAL CANCER RESEARCH

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA